The Lancet is one of the world's best known, oldest, and most
respected general medical jouals.
August 11–17, 2012
A medical crisis in Syria
Preventing hypertension: a hopeless dream?
Psychological maltreatment of children: everyone's problem
Hypertension: treatments, diabetes, and developing regions
Balancing the cardiometabolic benefits and risks of statins
Mendelian randomisation, lipids, and cardiovascular disease
Statins for all by the age of 50 years?
Cardiology, hypertension, and The Lancet
Offline: A good idea worth protecting
UK launches a new centre of excellence for stem cell research
India outlines plans for National Urban Health Mission
German doctors free to take cash from drug firms
Cohort reporting improves hypertension care for refugees
William Harvey: rebel malgré lui
Eesto Schiffrin: essential player in hypertension
Paul Ridker: reaching the end game
How much CABG is good for us?
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
New drugs, procedures, and devices for hypertension
Diabetes and hypertension: the bad companions
Hypertension in developing countries
Case Report - Lost in effusion
August 11–17, 2012
A medical crisis in Syria
Preventing hypertension: a hopeless dream?
Psychological maltreatment of children: everyone's problem
Hypertension: treatments, diabetes, and developing regions
Balancing the cardiometabolic benefits and risks of statins
Mendelian randomisation, lipids, and cardiovascular disease
Statins for all by the age of 50 years?
Cardiology, hypertension, and The Lancet
Offline: A good idea worth protecting
UK launches a new centre of excellence for stem cell research
India outlines plans for National Urban Health Mission
German doctors free to take cash from drug firms
Cohort reporting improves hypertension care for refugees
William Harvey: rebel malgré lui
Eesto Schiffrin: essential player in hypertension
Paul Ridker: reaching the end game
How much CABG is good for us?
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
New drugs, procedures, and devices for hypertension
Diabetes and hypertension: the bad companions
Hypertension in developing countries
Case Report - Lost in effusion